Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
about
Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies.TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.Ambivalent roles of carboxypeptidase B in the lytic susceptibility of fibrin.Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity.
P2860
Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@en
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@nl
type
label
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@en
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@nl
prefLabel
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@en
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@nl
P2093
P2860
P356
P1476
Activated thrombin-activatable ...... tect plasmin from antiplasmin.
@en
P2093
Erin Neill
Mark Schneider
Michael Nesheim
Nicole Brufatto
P2860
P304
13340-13345
P356
10.1074/JBC.M313211200
P407
P577
2004-01-08T00:00:00Z